Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Cut to $148.00 by Analysts at The Goldman Sachs Group

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) had its price target cut by The Goldman Sachs Group from $192.00 to $148.00 in a research note issued to investors on Wednesday morning, MarketBeat.com reports. They currently have a neutral rating on the specialty pharmaceutical company’s stock.

Other analysts also recently issued reports about the stock. HC Wainwright cut their target price on shares of Jazz Pharmaceuticals from $210.00 to $204.00 in a research note on Friday, August 5th. UBS Group cut their target price on shares of Jazz Pharmaceuticals from $194.00 to $191.00 and set a buy rating on the stock in a research note on Thursday, August 4th. StockNews.com raised shares of Jazz Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Tuesday. Morgan Stanley upped their price target on shares of Jazz Pharmaceuticals from $174.00 to $187.00 and gave the stock an equal weight rating in a research note on Thursday, August 4th. Finally, BMO Capital Markets upped their price target on shares of Jazz Pharmaceuticals from $185.00 to $188.00 and gave the stock an outperform rating in a research note on Thursday, August 4th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $200.00.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $133.28 on Wednesday. The company’s fifty day moving average is $154.39 and its two-hundred day moving average is $154.72. The company has a quick ratio of 2.45, a current ratio of 3.67 and a debt-to-equity ratio of 1.87. Jazz Pharmaceuticals has a 12-month low of $117.64 and a 12-month high of $169.98. The company has a market cap of $8.32 billion, a P/E ratio of -156.80, a price-to-earnings-growth ratio of 1.25 and a beta of 0.68.

Insider Transactions at Jazz Pharmaceuticals

In other news, SVP Samantha Pearce sold 8,508 shares of the company’s stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $155.00, for a total transaction of $1,318,740.00. Following the completion of the transaction, the senior vice president now directly owns 11,309 shares in the company, valued at $1,752,895. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, SVP Samantha Pearce sold 8,508 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $155.00, for a total transaction of $1,318,740.00. Following the sale, the senior vice president now directly owns 11,309 shares in the company, valued at $1,752,895. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 7,703 shares of the business’s stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $153.18, for a total value of $1,179,945.54. Following the sale, the chief executive officer now owns 353,311 shares in the company, valued at $54,120,178.98. The disclosure for this sale can be found here. Insiders sold a total of 48,764 shares of company stock worth $7,619,938 over the last three months. 4.40% of the stock is currently owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Jazz Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock valued at $872,164,000 after purchasing an additional 57,949 shares during the period. JPMorgan Chase & Co. increased its position in shares of Jazz Pharmaceuticals by 2.7% during the second quarter. JPMorgan Chase & Co. now owns 3,377,061 shares of the specialty pharmaceutical company’s stock valued at $526,855,000 after purchasing an additional 87,895 shares during the period. Wellington Management Group LLP grew its position in Jazz Pharmaceuticals by 7.5% in the first quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock valued at $408,654,000 after acquiring an additional 184,124 shares during the period. State Street Corp grew its position in Jazz Pharmaceuticals by 0.6% in the first quarter. State Street Corp now owns 2,345,235 shares of the specialty pharmaceutical company’s stock valued at $365,083,000 after acquiring an additional 14,293 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in Jazz Pharmaceuticals by 638.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,310,729 shares of the specialty pharmaceutical company’s stock valued at $166,987,000 after acquiring an additional 1,133,121 shares during the period. 92.79% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

(Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Read More

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.